Associated Papers
Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor.
Wegert J et al.
Genome Medicine, 2025
40340749 (PubMed )
Supplement: 13073_2025_1482_MOESM1_ESM.xlsx › Table_S2
Wilms tumor primary cultures capture phenotypic heterogeneity and facilitate preclinical screening.
Götz L et al.
Translational Oncology, 2025
39740515 (PubMed )
Supplement: mmc6.xlsx › Wilms_tumor_cultures
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Murphy AJ et al.
Nature Communications, 2023
38110397 (PubMed )
Supplement: 41467_2023_43730_MOESM5_ESM.xlsx › COG
Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses.
Brzezinski J et al.
British Journal of Cancer, 2021
33012783 (PubMed )
Supplement: 41416_2020_1102_MOESM7_ESM.xlsx › Sheet1
Deregulation of Drosha in the pathogenesis of hereditary hemorrhagic telangiectasia.
Hata A et al.
Current Opinion in Hematology, 2019
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J et al.
Cancer Cell, 2015
Select a paper to view details